PREFILED DEC 23 2019
|
REFERENCE TITLE: Lyme disease treatment |
|
State of Arizona House of Representatives Fifty-fourth Legislature Second Regular Session 2020
|
|
HB 2071 |
|
|
|
Introduced by Representatives Blackman: Biasiucci, Campbell, Carroll
|
AN ACT
Amending Title 32, chapter 32, article 1, Arizona Revised Statutes, by adding section 32‑3228; relating to health care professionals.
(TEXT OF BILL BEGINS ON NEXT PAGE)
Be it enacted by the Legislature of the State of Arizona:
Section 1. Title 32, chapter 32, article 1, Arizona Revised Statutes, is amended by adding section 32-3228, to read:
32-3228. Lyme disease treatment; definitions
A. A physician licensed pursuant to chapter 13 or 17 of this title, a nurse practitioner licensed pursuant to chapter 15 of this title or a physician assistant licensed pursuant to chapter 25 of this title may prescribe, administer or dispense long‑term antibiotic therapy for a therapeutic purpose to eliminate infection or to control a patient's symptoms after making a clinical diagnosis that the patient has Lyme disease or displays symptoms consistent with a clinical diagnosis of Lyme disease. The physician, nurse practitioner or physician assistant shall document the clinical diagnosis and treatment in the patient's medical record. The clinical diagnosis may be based on knowledge obtained through medical history and physical examination only or in conjunction with testing that provides supportive data for the clinical diagnosis.
B. For the purposes of this section:
1. "Long‑term antibiotic therapy" means the administration of oral, intramuscular or intravenous antibiotics, singly or in combination, for more than nineteen weeks.
2. "Lyme disease":
(a) Means any of the following:
(i) The presence of signs or symptoms compatible with acute infection with Borrelia burgdorferi.
(ii) Late stage, persistent or chronic infection with Borrelia burgdorferi.
(iii) Complications related to an infection under item (i) or (ii) of this subdivision.
(iv) The presence of signs or symptoms compatible with acute infection or late stage, persistent or chronic infection with other strains of Borrelia that are identified or recognized by the United States centers for disease control and prevention as a cause of disease.
(b) Includes an infection that meets the surveillance criteria for Lyme disease established by the United States centers for disease control and prevention or a clinical diagnosis of Lyme disease that does not meet the surveillance criteria for Lyme disease set by the United States centers for disease control and prevention but that presents other acute and chronic signs or symptoms of Lyme disease as determined by a patient's treating physician, nurse practitioner or physician assistant.
Sec. 2. Short title
This act may be cited as the "Ryan Montgomery Lyme Disease Treatment Act".